Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness
Primary Purpose
Acute Mountain Sickness, High Altitude Headache
Status
Completed
Phase
Not Applicable
Locations
Nepal
Study Type
Interventional
Intervention
Ibuprofen
Metoclopramide
Sponsored by
About this trial
This is an interventional treatment trial for Acute Mountain Sickness focused on measuring Acute Mountain Sickness, High Altitude Headache, Lake Louise AMS Score, Visual Analog Scale, Ibuprofen, Metoclopramide, Nepal
Eligibility Criteria
Inclusion Criteria:
- Presence at Manang recruitment center (at approximately 11,500 ft) during the dates March through May, 2012.
- Recent increase in altitude of > 1000 ft vertical in last 24 hours
- Presence of headache and at least one other symptom required for diagnosis of acute mountain sickness (including nausea, vomiting, fatigue, weakness, dizziness, lightheadedness or poor sleeping.)
Exclusion Criteria:
- Age less than 19 years old
- Known allergy or contraindication to either ibuprofen or metoclopramide
- Evidence of severe high altitude illness (e.g. High altitude pulmonary edema (HAPE) as evidenced by dyspnea at rest -- or of High Altitude Cerebral Edema (HACE) as evidenced by altered mental status or ataxia)
- Known or suspected pregnancy
- Use of other analgesic or antiemetic within 8 hours of study enrollment
- History of migraines or other chronic headache disorders
- Inability to provide informed consent
Sites / Locations
- Manang Clinic of the Himalayan Rescue Association
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Metoclopramide
Ibuprofen
Arm Description
150 subjects with acute mountain sickness will be randomly assigned to take metoclopramide.
150 subjects with acute mountain sickness will be randomly assigned to take ibuprofen.
Outcomes
Primary Outcome Measures
Headache and Nausea Visual Analog Scales
Subjects will complete 100mm visual analog scales of both headache and nausea at time zero, 30, 60, and 120 minutes after taking the study medication. Visual analog scales are a valid assessment of symptom severity for acute mountain sickness.
Secondary Outcome Measures
Lake Louise Acute Mountain Sickness Score
Subjects will take the Lake Louise Acute Mountains Sickness score before taking the medication and 120 minutes after taking the medication. The Lake Louise Acute Mountain Sickness Score is a standard measure of the severity of acute mountain sickness and is commonly used in studies involving acute mountain sickness.
Full Information
NCT ID
NCT01522326
First Posted
January 27, 2012
Last Updated
September 1, 2020
Sponsor
Massachusetts General Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01522326
Brief Title
Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness
Official Title
Acute Mountain Sickness Treatment: A Double-blind Comparison of Metoclopramide vs. Ibuprofen
Study Type
Interventional
2. Study Status
Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
March 1, 2012 (undefined)
Primary Completion Date
March 1, 2017 (Actual)
Study Completion Date
March 30, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of this study is to determine the efficacy of metoclopramide in relieving the symptoms of Acute Mountain Sickness (AMS).
It is our hypothesis that the combined antiemetic and analgesic effects of metoclopramide (which has been study-proven to be effective in relieving symptoms of migraine headache) will prove to be more efficacious in relieving symptoms of acute mountain sickness than the standard, previously-studied analgesic medication, ibuprofen.
Detailed Description
Acute Mountain Sickness (AMS) is a well described disease process that occurs as a result of rapid exposure to high altitude. High altitude headache (HAH) is defined as the presence of headache in the setting of a recent increase in altitude. When HAH is associated with nausea, vomiting, fatigue, weakness, dizziness, lightheadedness or poor sleeping, AMS is diagnosed. While benign, AMS is very common, afflicting up to 80 % of travelers who ascend rapidly to 14,000 ft, and can be debilitating. AMS is thought to occur secondary to hypoxia-induced cerebral vasodilation. The antiemetic metoclopramide has been well studied and is commonly administered for treatment of migraine headaches in emergency departments across the U.S. The symptoms of migraine headaches are often similar to those of AMS. The mechanism of metoclopramide"s beneficial effect in this indication appear to be a result of its antagonism of central and peripheral dopamine receptors,most notably by blocking stimulation of the medullary chemoreceptor trigger zone. No studies have yet evaluated the potential benefits of metoclopramide for the relief of AMS. In contrast, ibuprofen has been well studied and found to be an effective treatment for the relief of symptoms of high altitude headache and AMS.
The study will be a convenience sample of trekkers traveling through the Annapurna Circuit in Nepal during the 3 month time period of March-May, 2012. Subjects will be recruited from visitors to Manang, Nepal staying in local hostels, those visiting the Himalayan Rescue Association clinic in Manang, and those responding to locally posted signage regarding study enrollment.
Eligible patients will be consented and enrolled in the study. Patients will be randomized to receive either Ibuprofen 400mg or Metoclopramide 10mg by mouth. Investigators will be blinded as to which arm of the study the patient is enrolled. Participants will be assessed by Lake Louise Score and Visual Analog Scale for headache and nausea severity immediately prior to ingestion of study medication, and then serially at 30, 60, and 120 minutes following medication ingestion. Standard statistical analysis of the Lake Louise AMS scores and visual analog scales will be used to determine which medication is more effective in treating acute mountain sickness.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Mountain Sickness, High Altitude Headache
Keywords
Acute Mountain Sickness, High Altitude Headache, Lake Louise AMS Score, Visual Analog Scale, Ibuprofen, Metoclopramide, Nepal
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
300 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Metoclopramide
Arm Type
Experimental
Arm Description
150 subjects with acute mountain sickness will be randomly assigned to take metoclopramide.
Arm Title
Ibuprofen
Arm Type
Active Comparator
Arm Description
150 subjects with acute mountain sickness will be randomly assigned to take ibuprofen.
Intervention Type
Drug
Intervention Name(s)
Ibuprofen
Other Intervention Name(s)
Advil, Motrin
Intervention Description
Ibuprofen 400mg tablet. Take one dose by mouth.
Intervention Type
Drug
Intervention Name(s)
Metoclopramide
Other Intervention Name(s)
Reglan
Intervention Description
Metoclopramide 10mg tablet. Take one tablet by mouth.
Primary Outcome Measure Information:
Title
Headache and Nausea Visual Analog Scales
Description
Subjects will complete 100mm visual analog scales of both headache and nausea at time zero, 30, 60, and 120 minutes after taking the study medication. Visual analog scales are a valid assessment of symptom severity for acute mountain sickness.
Time Frame
120 minutes
Secondary Outcome Measure Information:
Title
Lake Louise Acute Mountain Sickness Score
Description
Subjects will take the Lake Louise Acute Mountains Sickness score before taking the medication and 120 minutes after taking the medication. The Lake Louise Acute Mountain Sickness Score is a standard measure of the severity of acute mountain sickness and is commonly used in studies involving acute mountain sickness.
Time Frame
120 minutes
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Presence at Manang recruitment center (at approximately 11,500 ft) during the dates March through May, 2012.
Recent increase in altitude of > 1000 ft vertical in last 24 hours
Presence of headache and at least one other symptom required for diagnosis of acute mountain sickness (including nausea, vomiting, fatigue, weakness, dizziness, lightheadedness or poor sleeping.)
Exclusion Criteria:
Age less than 19 years old
Known allergy or contraindication to either ibuprofen or metoclopramide
Evidence of severe high altitude illness (e.g. High altitude pulmonary edema (HAPE) as evidenced by dyspnea at rest -- or of High Altitude Cerebral Edema (HACE) as evidenced by altered mental status or ataxia)
Known or suspected pregnancy
Use of other analgesic or antiemetic within 8 hours of study enrollment
History of migraines or other chronic headache disorders
Inability to provide informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Norman S Harris, MD, MFA
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Manang Clinic of the Himalayan Rescue Association
City
Manang
State/Province
District Of Manang
ZIP/Postal Code
33500
Country
Nepal
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
Citation
Roach RC, Bartsch P, Hackett PH, Oelz O. The Lake Louise acute mountain sickness scoring system. Hypoxia and Molecular Medicine, J.R. Sutton, C. S. Huston, and G. Coates eds. Burlinton, VT, USA: Queen City Printers; 1993.
Results Reference
background
PubMed Identifier
6351209
Citation
Gilbert DL. The first documented report of mountain sickness: the China or Headache Mountain story. Respir Physiol. 1983 Jun;52(3):315-26. doi: 10.1016/0034-5687(83)90088-9.
Results Reference
background
PubMed Identifier
6351210
Citation
Gilbert DL. The first documented description of mountain sickness: the Andean or Pariacaca story. Respir Physiol. 1983 Jun;52(3):327-47. doi: 10.1016/0034-5687(83)90089-0.
Results Reference
background
Citation
Hultgren HN. High Altitude Pulmonary Edema. High Altitude Medicine. Stanford, CA: Hultgren Publications; 1997.
Results Reference
background
PubMed Identifier
2911169
Citation
Montgomery AB, Mills J, Luce JM. Incidence of acute mountain sickness at intermediate altitude. JAMA. 1989 Feb 3;261(5):732-4.
Results Reference
background
PubMed Identifier
2282425
Citation
Maggiorini M, Buhler B, Walter M, Oelz O. Prevalence of acute mountain sickness in the Swiss Alps. BMJ. 1990 Oct 13;301(6756):853-5. doi: 10.1136/bmj.301.6756.853.
Results Reference
background
PubMed Identifier
12471292
Citation
Schneider M, Bernasch D, Weymann J, Holle R, Bartsch P. Acute mountain sickness: influence of susceptibility, preexposure, and ascent rate. Med Sci Sports Exerc. 2002 Dec;34(12):1886-91. doi: 10.1097/00005768-200212000-00005.
Results Reference
background
PubMed Identifier
11450659
Citation
Hackett PH, Roach RC. High-altitude illness. N Engl J Med. 2001 Jul 12;345(2):107-14. doi: 10.1056/NEJM200107123450206. No abstract available.
Results Reference
background
PubMed Identifier
2028586
Citation
Ellsworth AJ, Meyer EF, Larson EB. Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. West J Med. 1991 Mar;154(3):289-93.
Results Reference
background
PubMed Identifier
3051673
Citation
Zell SC, Goodman PH. Acetazolamide and dexamethasone in the prevention of acute mountain sickness. West J Med. 1988 May;148(5):541-5.
Results Reference
background
PubMed Identifier
62991
Citation
Hackett PH, Rennie D, Levine HD. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet. 1976 Nov 27;2(7996):1149-55. doi: 10.1016/s0140-6736(76)91677-9.
Results Reference
background
PubMed Identifier
8117220
Citation
Broome JR, Stoneham MD, Beeley JM, Milledge JS, Hughes AS. High altitude headache: treatment with ibuprofen. Aviat Space Environ Med. 1994 Jan;65(1):19-20.
Results Reference
background
PubMed Identifier
20832701
Citation
Gertsch JH, Lipman GS, Holck PS, Merritt A, Mulcahy A, Fisher RS, Basnyat B, Allison E, Hanzelka K, Hazan A, Meyers Z, Odegaard J, Pook B, Thompson M, Slomovic B, Wahlberg H, Wilshaw V, Weiss EA, Zafren K. Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness Environ Med. 2010 Sep;21(3):236-43. doi: 10.1016/j.wem.2010.06.009. Epub 2010 Jun 16.
Results Reference
background
PubMed Identifier
12745039
Citation
Harris NS, Wenzel RP, Thomas SH. High altitude headache: efficacy of acetaminophen vs. ibuprofen in a randomized, controlled trial. J Emerg Med. 2003 May;24(4):383-7. doi: 10.1016/s0736-4679(03)00034-9.
Results Reference
background
PubMed Identifier
20393963
Citation
Kirthi V, Derry S, Moore RA, McQuay HJ. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD008041. doi: 10.1002/14651858.CD008041.pub2.
Results Reference
background
PubMed Identifier
17981511
Citation
Griffith JD, Mycyk MB, Kyriacou DN. Metoclopramide versus hydromorphone for the emergency department treatment of migraine headache. J Pain. 2008 Jan;9(1):88-94. doi: 10.1016/j.jpain.2007.09.001. Epub 2007 Nov 5.
Results Reference
background
PubMed Identifier
15699376
Citation
Friedman BW, Corbo J, Lipton RB, Bijur PE, Esses D, Solorzano C, Gallagher EJ. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology. 2005 Feb 8;64(3):463-8. doi: 10.1212/01.WNL.0000150904.28131.DD.
Results Reference
background
PubMed Identifier
15550401
Citation
Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ. 2004 Dec 11;329(7479):1369-73. doi: 10.1136/bmj.38281.595718.7C. Epub 2004 Nov 18.
Results Reference
background
Citation
The Lake Louise Consensus on the Definition and Quantification of Altitude Illness. In: Sutton J, Coates G, Houston C, eds. Hypoxia and Molecular Medicine. Burlington, VT: Queen City Printers; 1993.
Results Reference
background
PubMed Identifier
20367491
Citation
Kayser B, Aliverti A, Pellegrino R, Dellaca R, Quaranta M, Pompilio P, Miserocchi G, Cogo A. Comparison of a visual analogue scale and Lake Louise symptom scores for acute mountain sickness. High Alt Med Biol. 2010 Spring;11(1):69-72. doi: 10.1089/ham.2009.1046.
Results Reference
background
Learn more about this trial
Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness
We'll reach out to this number within 24 hrs